鼻咽頭がん(Nasopharyngeal Cancer)の治療薬パイプライン動向（2015年上半期版）...市場調査レポートについてご紹介

Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Nasopharyngeal Cancer Overview 9
Therapeutics Development 10
Pipeline Products for Nasopharyngeal Cancer – Overview 10
Pipeline Products for Nasopharyngeal Cancer – Comparative Analysis 11
Nasopharyngeal Cancer – Therapeutics under Development by Companies 12
Nasopharyngeal Cancer – Therapeutics under Investigation by Universities/Institutes 14
Nasopharyngeal Cancer – Pipeline Products Glance 16
Clinical Stage Products 16
Early Stage Products 17
Nasopharyngeal Cancer – Products under Development by Companies 18
Nasopharyngeal Cancer – Products under Investigation by Universities/Institutes 19
Nasopharyngeal Cancer – Companies Involved in Therapeutics Development 20
Ambrx, Inc. 20
AVEO Pharmaceuticals, Inc. 21
BioDiem Ltd 22
Celgene Corporation 23
Cyclacel Pharmaceuticals, Inc. 24
F. Hoffmann-La Roche Ltd. 25
GlaxoSmithKline plc 26
Merck & Co., Inc. 27
Otsuka Holdings Co., Ltd. 28
Pharmacyclics, Inc. 29
Theravectys S.A. 30
Zhejiang BetaPharma Co., Ltd. 31
Nasopharyngeal Cancer – Therapeutics Assessment 32
Assessment by Monotherapy Products 32
Assessment by Combination Products 33
Assessment by Target 34
Assessment by Mechanism of Action 36
Assessment by Route of Administration 38
Assessment by Molecule Type 40
Drug Profiles 42
abexinostat hydrochloride – Drug Profile 42
Product Description 42
Mechanism of Action 42
R&D Progress 42
azacitidine – Drug Profile 44
Product Description 44
Mechanism of Action 44
R&D Progress 44
Cell Therapy 2 for Oncology and Infectious Disease – Drug Profile 47
Product Description 47
Mechanism of Action 47
R&D Progress 47
Cell Therapy for Metastatic Nasopharyngeal Carcinoma and Colorectal Cancer – Drug Profile 48
Product Description 48
Mechanism of Action 48
R&D Progress 48
Cell Therapy for Nasopharingeal Carcinoma – Drug Profile 49
Product Description 49
Mechanism of Action 49
R&D Progress 49
Cell Therapy to Target Latent Membrane Protein-2 for Oncology – Drug Profile 50
Product Description 50
Mechanism of Action 50
R&D Progress 50
Cell Therapy to Target LMP-1 and LMP-2 for Metastatic Nasopharyngeal Carcinoma – Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
Cell Therapy to Target LMP-1 and LMP-2 for Oncology – Drug Profile 52
Product Description 52
Mechanism of Action 52
R&D Progress 52
Dendritic Cells + Cytokine Induced Killer Cells – Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
EBV-nRNA – Drug Profile 54
Product Description 54
Mechanism of Action 54
R&D Progress 54
ficlatuzumab – Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
Gene Therapy to Activate p53 for Oncology – Drug Profile 58
Product Description 58
Mechanism of Action 58
R&D Progress 58
GSK-2849330 – Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
icotinib hydrochloride – Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
MK-2206 – Drug Profile 61
Product Description 61
Mechanism of Action 61
R&D Progress 61
Monoclonal Antibody Drug Conjugate to Inhibit CD70 for Nasopharyngeal Cancer and Renal Cell Carcinoma – Drug Profile 64
Product Description 64
Mechanism of Action 64
R&D Progress 64
NEO-212 – Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
OPB-51602 – Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
RO-5203280 – Drug Profile 67
Product Description 67
Mechanism of Action 67
R&D Progress 67
seliciclib – Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
Small Molecules for Nasopharyngeal and Colon Cancers – Drug Profile 70
Product Description 70
Mechanism of Action 70
R&D Progress 70
Stem Cell Therapy for Oncology – Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
Vaccine for EBV Associated Nasopharyngeal Cancer – Drug Profile 72
Product Description 72
Mechanism of Action 72
R&D Progress 72
Vaccine for Epstein-Barr Viral Infections and Nasopharyngeal Cancer – Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
Vaccine to Target EBV for Nasopharyngeal Carcinoma – Drug Profile 74
Product Description 74
Mechanism of Action 74
R&D Progress 74
Nasopharyngeal Cancer – Recent Pipeline Updates 75
Nasopharyngeal Cancer – Dormant Projects 80
Nasopharyngeal Cancer – Product Development Milestones 81
Featured News & Press Releases 81
Dec 16, 2011: Radiation Therapy Oncology Group Trial Results Show Bevacizumab Reduces Spread Of Nasopharyngeal Cancer 81
May 29, 2009: Cyclacel Reports Initial Phase 2 Seliciclib Data In Patients With Nasopharyngeal Carcinoma At 2009 Asco Annual Meeting 82
Apr 21, 2009: Cyclacel & Dartmouth Researchers Reports Novel Mechanism Of Action For Seliciclib At AACR 82
Mar 05, 2009: Cyclacel Announces Phase 1 Data Elucidating Pharmacodynamics & Mechanism Of Action Of Seliciclib In Nasopharyngeal Cancer 83
Aug 28, 2008: CYCLACEL Announces Recommendations Of Data Review Committee For Seliciclib Phase 2b Non-Small Cell Lung Cancer APPRAISE Trial 84
Jun 28, 2007: Cyclacel Pharmaceuticals Announces Results Of Phase II Seliciclib Combination Studies 84
Appendix 86
Methodology 86
Coverage 86
Secondary Research 86
Primary Research 86
Expert Panel Validation 86
Contact Us 87
Disclaimer 87